Oppenheimer Reiterates Outperform Rating, $39 PT on Mindray Medical International

In a report published Monday, Oppenheimer reiterated its Outperform rating and $39.00 price target on Mindray Medical International Ltd. MR. Oppenheimer noted, “Shenzhen Medical Device export data showed 4% yoy growth in November, compared with 12% in October. B&W ultrasound and anesthesia machines stayed robust, growing 33% and 45%, respectively. Weakness mostly stems from the 10% decline in patient monitors. If using September, October and November data together, ShenZhen medical device grew 7.5%, compared with 4.8% in the previous quarter, showing signs of recovery. Considering strong emerging market demand, despite uncertainties in the US and Europe we still hold an 11% ex-China growth estimate for MR's 4Q12.” Mindray Medical International Ltd. closed on Friday at $33.01.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorReiterationAnalyst RatingsOppenheimer Holdings
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!